CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

dinoprostone

Trade name: prostin e2

Small moleculeapproved

Approved

Aug 23, 1977

5-trans-Prostaglandin E2 is the trans isomer of prostaglandin E2 and a common impurity in commercial lots of PGE1, that occurs naturally in some gorgonian corals. 5-trans-Prostaglandin E2 , a more potent than prostaglandin E2 in activating adenylate cyclase in NCB-20 cell homogenates. 5-trans PGE2 accelerates fibrinolysis by enhancing plasminogen activation mediated by tissue-type plasminogen activator and It also inhibits platelet aggregation/ 5-trans-Prostaglandin E2 is used as a substance for the isolation of new naturally occuring prostaglandin 5-trans-PGA2 and in the synthesis of 5-trans-PGF2a. — NCATS

Clinical trial activity

80 trials · 67 clinical orgs · 4 marketing orgs

Phase 1
2
Phase 2
28
Phase 3
22
Phase 4
24

Earliest trial started Apr 1, 1999 (NCT03489928)

Timeline

1970s

  1. Aug 23, 1977

    Upjohn — Earliest FDA Approval

  2. Aug 23, 1977

    Pharmacia & Upjohn — NDA Secondary Org

  3. Aug 23, 1977

    Pfizer — Marketing Organization

  4. Aug 23, 1977

    Upjohn — NDA Organization

  5. Aug 23, 1977

    Pfizer — NDA Secondary Org

1990s

  1. Mar 30, 1995

    Ferring — NDA Secondary Org

  2. Jan 1, 1999

    Earliest Phase 3 Sponsor(trial)

2000s

  1. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2012

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedPriority reviewAug 23, 1977

Chemistry & pharmacology

Loading structure…

SMILES

CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
Mol. weight
352.4651 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral, Topical
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

Yes

Sources

Also known as

  • (15s)-prostaglandin e2
  • (15s)-prostaglandin e2
  • (5z,11alpha,13e,15s)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
  • (5z,11alpha,13e,15s)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
  • (5z,13e)-(15s)-11alpha,15-dihydroxy-9-oxoprost-13-enoate
  • (5z,13e)-(15s)-11alpha,15-dihydroxy-9-oxoprost-13-enoate
  • (5z,13e)-(15s)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
  • (5z,13e)-(15s)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
  • cervidil
  • cervidil
  • cervidil
  • cerviprost
  • dinoproston
  • dinoproston
  • dinoprostona
  • dinoprostona
  • dinoprostone
  • dinoprostone
  • dinoprostone
  • dinoprostone
  • dinoprostone
  • dinoprostone
  • dinoprostone
  • dinoprostone
  • dinoprostone
  • dinoprostone
  • dinoprostone
  • dinoprostone
  • dinoprostone beta-cyclodextrin clathrate
  • dinoprostone beta-cyclodextrin clathrate
  • dinoprostone prostaglandin e2
  • dinoprostone prostaglandin e2
  • dinoprostonum
  • dinoprostonum
  • (e,z)-(1r,2r,3r)-7-(3-hydroxy-2-((3s)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid
  • (e,z)-(1r,2r,3r)-7-(3-hydroxy-2-((3s)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid
  • minprositin e2
  • minprostin
  • minprostin
  • pge2
  • pge2
  • pge2
  • primiprost
  • propess
  • propess
  • propess
  • prostaglandin e2
  • prostaglandin e2
  • prostin e2
  • prostin e2
  • u-12062
  • u-12062
  • (z)-7-((1r,2r,3r)-3-hydroxy-2-((s,e)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid
  • (z)-7-((1r,2r,3r)-3-hydroxy-2-((s,e)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06803992Phase 4Jan 29, 2025Emek Medical Center
NCT06794385Phase 4Jan 22, 2025University of Ljubljana
NCT05774236Phase 3Mar 27, 2023Spanish Clinical Research Network, Universidad Carlos III Madrid, Universidad Complutense de Madrid
NCT06560515N/AAug 1, 2022Alexandria University
NCT05430711Phase 4Jun 30, 2022University of Ljubljana
NCT05342467Phase 2Nov 11, 2021National University of Malaysia
NCT04747301N/AMar 12, 2021Hanoi Obstetric and Gynecology Hospital, Hanoi Obstetrics and Gynecology Hospital, Monash University, My Duc Phu Nhuan Hospital
NCT04500496N/ASep 1, 2020Aswan University
NCT04500509N/ASep 1, 2020Aswan University
NCT04505917N/ASep 1, 2020Aswan University
NCT04505943N/ASep 1, 2020Aswan University
NCT04357002Phase 4Apr 30, 2020Cairo University
NCT04340778Phase 3Apr 30, 2020Cairo University
NCT04339361Phase 4Apr 25, 2020Cairo University
NCT04301349Phase 3Mar 15, 2020Cairo University
NCT04413890Phase 2Dec 16, 2019University Hospital Center of Martinique, University hospital of Martinique
NCT04080349Phase 4Sep 10, 2019Cairo University
NCT04080323Phase 3Sep 10, 2019Al Azhar University, Cairo University
NCT04080336Phase 4Sep 10, 2019Cairo University
NCT04080375Phase 3Sep 10, 2019Cairo University
Showing 20 of 80 trials
Page 1 / 4

Organizations

Research & Development (67)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Cairo UniversityAcademic/Hospital171632018
FerringFor profit7532006
Seoul National UniversityAcademic/Hospital5522012
Ain Shams UniversityAcademic/Hospital4422010
Aswan UniversityAcademic/Hospital4412020
Technion UniversityAcademic/Hospital3312016
Medicem InternationalFor profit2022017
Tel Aviv UniversityAcademic/Hospital2222016
University of CopenhagenAcademic/Hospital2122002
University of LjubljanaAcademic/Hospital2212022
AFP Innovation FundAcademic/Hospital1012016
Al Azhar UniversityAcademic/Hospital1012019
Alexandria UniversityAcademic/Hospital1112022
Aljazeera HospitalAcademic/Hospital1112018
Allegiance HealthAcademic/Hospital1112019
Basque Health ServiceAcademic/Hospital1112016
Beni Suef UniversityAcademic/Hospital1112018
Centre Hospitalier Departemental VendeeAcademic/Hospital1112016
Clinical Hospital MerkurAcademic/Hospital1112018
Cornell UniversityAcademic/Hospital1112002
67 organizations
Page 1 / 4

Marketing (5)

OrganizationOrg typeRelationshipDate
FerringFor profitNDA2Mar 30, 1995
PfizerFor profitMKTGAug 23, 1977
PfizerFor profitNDA2Aug 23, 1977
Pharmacia & UpjohnFor profitNDA2Aug 23, 1977
UpjohnFor profitNDAAug 23, 1977